Related Experiment Video

Updated: Jun 6, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers

Vladimir A Krutovskikh1, Zdenko Herceg

  • 1International Agency for Research on Cancer (IARC), Lyon, France.

Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology
|November 25, 2010
PubMed

Insights

MicroRNAs (miRs) are small non-coding RNAs crucial in cancer research. Their deregulation contributes to cancer, and their unique expression patterns make them promising biomarkers for early diagnosis and novel cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Small non-coding RNAs, specifically microRNAs (miRs), are pivotal in cancer research, challenging traditional cancer concepts.
  • miRs regulate oncoprotein expression; their deregulation is implicated in cancer development and progression.
  • miRs are promising cancer biomarkers due to distinct expression patterns, stability, and presence in body fluids.

Purpose of the Study:

  • To highlight the significance of microRNAs in understanding cancer.
  • To emphasize the potential of miRs as biomarkers for cancer diagnosis and prognosis.
  • To explore the role of miRs in developing novel cancer prevention and therapeutic strategies.

Main Methods:

  • Review of current research on microRNA function in cancer.
  • Analysis of microRNA expression patterns in various cancer types.
  • Investigation of microRNA stability and detectability in biological fluids.

Main Results:

  • MicroRNA deregulation is a key mechanism in cancer development.
  • "miR signatures" link cancer phenotypes to outcomes and risk factors.
  • MicroRNAs show high potential as stable, detectable biomarkers.

Conclusions:

  • MicroRNAs necessitate a re-evaluation of cancer biology.
  • Identifying "miR signatures" offers new pathways for early cancer diagnosis and treatment.
  • MicroRNAs are instrumental in developing innovative cancer prevention strategies.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...